Beigel, 1,062 patient remdesivir late treatment RCT: 27% lower mortality [p=0.07] and 22% improved recovery [p=0.0005] https://c19p.org/beigel
copied to clipboard
Remdesivir for the Treatment of Covid-19 — Final Report
et al., NEJM, doi:10.1056/NEJMoa2007764
RCT 1,062 hospitalized patients showing faster recovery time with treatment, median 10 days vs. 15 days for placebo, rate ratio for recovery 1.29, p<0.001. Day 29 mortality was 11.4% with remdesivir and 15.2% with placebo, hazard ratio HR 0.73 [0.52-1.03].[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
|
risk of death, 27.0% lower, HR 0.73, p = 0.07, treatment 541, control 521.
|
|
risk of no recovery, 22.5% lower, RR 0.78, p < 0.001, treatment 541, control 521.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Beigel et al., 10/8/2020, Randomized Controlled Trial, USA, North America, peer-reviewed, 12 authors, average treatment delay 9.0 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.